David Leppert

16.6k total citations · 6 hit papers
170 papers, 10.5k citations indexed

About

David Leppert is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Neurology. According to data from OpenAlex, David Leppert has authored 170 papers receiving a total of 10.5k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Pathology and Forensic Medicine, 46 papers in Molecular Biology and 43 papers in Neurology. Recurrent topics in David Leppert's work include Multiple Sclerosis Research Studies (80 papers), Skin and Cellular Biology Research (28 papers) and Protease and Inhibitor Mechanisms (22 papers). David Leppert is often cited by papers focused on Multiple Sclerosis Research Studies (80 papers), Skin and Cellular Biology Research (28 papers) and Protease and Inhibitor Mechanisms (22 papers). David Leppert collaborates with scholars based in Switzerland, United States and United Kingdom. David Leppert's co-authors include Jens Kühle, Ludwig Kappos, Christian Barro, Stephen L. Leib, Edward J. Goetzl, Raija L.P. Lindberg, Pascal Benkert, Stephen L. Hauser, Michael J. Banda and Emmanuelle Waubant and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

David Leppert

166 papers receiving 10.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis

2017 819 citations Christian Barro, Pascal Benkert et al. Annals of Neurology profile →
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

2011 538 citations Ludwig Kappos, David Leppert et al. profile →
Serum neurofilament light levels in normal aging and their association with morphologic brain changes

2020 380 citations Michael Khalil, Lukas Pirpamer et al. profile →
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

2019 379 citations Jens Kühle, Harald Kropshofer et al. Neurology profile →
Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

2018 367 citations Christian Barro, Pascal Benkert et al. profile →
Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

2013 366 citations Ludwig Kappos, David Leppert et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
David Leppert	3.8k	2.9k	2.4k	1.8k	1.6k	170	10.5k
Bernd C. Kieseier	4.8k 1.3×	4.3k 1.5×	1.9k 0.8×	2.0k 1.1×	2.5k 1.5×	274	11.6k
Edgar Meinl	3.7k 0.9×	2.3k 0.8×	2.7k 1.1×	1.8k 1.0×	5.0k 3.0×	151	11.8k
Chi‐Chao Chan	1.7k 0.4×	1.8k 0.6×	4.7k 1.9×	1.9k 1.0×	4.7k 2.9×	397	18.4k
Alastair Compston	6.1k 1.6×	1.7k 0.6×	2.9k 1.2×	1.5k 0.9×	3.3k 2.0×	128	12.0k
Alexandre Prat	3.7k 1.0×	1.8k 0.6×	4.6k 1.9×	2.0k 1.1×	5.1k 3.1×	209	16.2k
Neil Scolding	2.4k 0.6×	1.7k 0.6×	2.2k 0.9×	665 0.4×	1.3k 0.8×	218	7.9k
Masato Koike	1.3k 0.3×	1.8k 0.6×	6.6k 2.7×	1.3k 0.8×	2.2k 1.3×	215	16.4k
Joachim Weis	825 0.2×	2.3k 0.8×	4.9k 2.1×	1.3k 0.8×	1.3k 0.8×	395	13.8k
Peter Rieckmann	6.8k 1.8×	2.9k 1.0×	2.2k 0.9×	2.4k 1.3×	3.1k 1.9×	266	13.1k
Finn Sellebjerg	6.0k 1.5×	2.5k 0.9×	1.7k 0.7×	2.5k 1.4×	3.4k 2.1×	315	10.3k

Countries citing papers authored by David Leppert

Since Specialization

Citations

This map shows the geographic impact of David Leppert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Leppert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Leppert more than expected).

Fields of papers citing papers by David Leppert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Leppert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Leppert. The network helps show where David Leppert may publish in the future.

Co-authorship network of co-authors of David Leppert

This figure shows the co-authorship network connecting the top 25 collaborators of David Leppert. A scholar is included among the top collaborators of David Leppert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Leppert. David Leppert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Booth, Ronald A., Daniel R. Beriault, Raphaël Schneider, et al.. (2025). Validation and generation of age-specific reference intervals for a new blood neurofilament light chain assay. Clinica Chimica Acta. 577. 120447–120447. 2 indexed citations

Saraste, Maija, Marjo Nylund, Markus Matilainen, et al.. (2025). Plasma CHI3L1 associates with brain volume loss and glial activation in multiple sclerosis. Journal of Neurology Neurosurgery & Psychiatry. 96(11). 1053–1060. 1 indexed citations

Moser, Tobias, Michael Khalil, Jens Kühle, et al.. (2025). Transient Global Amnesia (TGA): Is It Really Benign? A Pilot Study on Blood Biomarkers. International Journal of Molecular Sciences. 26(6). 2629–2629.

Leppert, David, Mitsuru Watanabe, Sabine Schaedelin, et al.. (2023). Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis. Journal of Neurology Neurosurgery & Psychiatry. 94(9). 726–737. 9 indexed citations

Saraste, Maija, Markus Matilainen, Marcus Sucksdorff, et al.. (2023). Association of serum neurofilament light with microglial activation in multiple sclerosis. Journal of Neurology Neurosurgery & Psychiatry. 94(9). 698–706. 14 indexed citations

Buchmann, Arabella, Lukas Pirpamer, Daniela Pinter, et al.. (2023). High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis. European Journal of Neurology. 30(5). 1389–1399. 8 indexed citations

Leppert, David, Harald Kropshofer, Dieter A. Häring, et al.. (2022). Blood Neurofilament Light in Progressive Multiple Sclerosis. Neurology. 98(21). e2120–e2131. 33 indexed citations

Probert, Fay, Tianrong Yeo, Yifan Zhou, et al.. (2021). Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis. Brain Communications. 3(2). fcab084–fcab084. 15 indexed citations

Kühle, Jens, Nadia Daizadeh, Pascal Benkert, et al.. (2021). Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS. Multiple Sclerosis Journal. 28(4). 573–582. 26 indexed citations

10.

Kühle, Jens, David Leppert, Gıancarlo Comı, et al.. (2021). Investigating the Correlation Between Serum Neurofilament Light Chain (sNfL) Concentration and Magnetic Resonance Imaging (MRI)-Outcomes in Patients With a First Clinical Demyelinating Event in the REFLEX Trial (1116). Neurology. 96(15_supplement). 1 indexed citations

11.

Sutter, Raoul, Lisa Hert, Gian Marco De Marchis, et al.. (2020). Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. Annals of Neurology. 89(3). 610–616. 54 indexed citations

12.

Maia, Luı́s F., Aleksandra Maleska Maceski, Isabel Conceição, et al.. (2020). Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid. 27(2). 97–102. 43 indexed citations

13.

Körtvelyessy, Péter, Jens Kühle, Emrah Düzel, et al.. (2020). Ratio and index of Neurofilament light chain indicate its origin in Guillain‐Barré Syndrome. Annals of Clinical and Translational Neurology. 7(11). 2213–2220. 33 indexed citations

14.

Watanabe, Mitsuru, Yuri Nakamura, Zuzanna Michalak, et al.. (2019). Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology. 93(13). e1299–e1311. 161 indexed citations

15.

Sormani, Maria Pia, Dieter Haering, Harald Kropshofer, et al.. (2019). Blood neurofilament light as a potential endpoint in Phase 2 studies in MS. Annals of Clinical and Translational Neurology. 6(6). 1081–1089. 42 indexed citations

16.

Smith, Paul, Catherine Huck, Diethilde Theil, et al.. (2017). Ofatumumab Differs from Rituximab by Effectively Targeting Lymph Node B cells and Achieving Faster Post-treatment Repletion (S24.003). Neurology. 88(16_supplement). 5 indexed citations

17.

Henry, Roland G., Yan Li, Alyssa H. Zhu, et al.. (2015). 1-H MRSI in patients with relapsing multiple sclerosis at 7 Tesla (P6.121). Neurology. 84(14_supplement). 2 indexed citations

18.

Palanichamy, Arumugam, Sarah Jahn, Dorothee Nickles, et al.. (2014). Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients. The Journal of Immunology. 193(2). 580–586. 215 indexed citations

19.

Anthony, Daniel C., et al.. (2009). Oral fingolimod (FTY720) therapy reduces blood brain barrier breakdown, microglial activation, and leukocyte recruitment in a focal DTH model of multiple sclerosis. Multiple Sclerosis Journal. 15. 1 indexed citations

20.

Fuhr, Peter & David Leppert. (2000). Cardiac arrest during partial seizure. Neurology. 54(10). 2026–2026. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact